Earnings Feed
Start Free
Xeris Biopharma Holdings, Inc.·4

Jun 5, 6:29 PM ET

PERSKY MARLA 4

4 · Xeris Biopharma Holdings, Inc. · Filed Jun 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Xeris (XERS) Director Marla Persky Sells 15,500 Shares & Receives Awards

What Happened

  • Marla Persky, a director of Xeris Biopharma (XERS), sold 15,500 shares in an open-market transaction on June 3, 2026 for a weighted average price of $5.90, generating proceeds of $91,433.
  • On June 4, 2026 she was reported as receiving two awards: 24,193 restricted stock units (RSUs) (acquired at $0) and a derivative award of 32,996 shares reported at $6.15 (listed value $202,925). The derivative award is a stock‑option style grant per the filing.

Key Details

  • Transaction dates: sale on 2026-06-03; awards reported 2026-06-04. Form filed 2026-06-05 (timely).
  • Sale details: weighted average sale price $5.90; individual sale prices ranged $5.810–$5.960. Sale was made under a Rule 10b5-1 trading plan adopted June 12, 2025.
  • RSUs (24,193): granted under the 2018 Plan; represent contingent rights to one share each and vest in full on the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service.
  • Options/derivative (32,996): granted under the Plan and vest in full on the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service. Filing reports these at $6.15 ($202,925).
  • Beneficial ownership: the reporting person disclaims beneficial ownership except to the extent of pecuniary interest; the Form does not list total shares owned after these transactions.
  • Filing timeliness: included in a Form 4 filed June 5, 2026 — not marked late.

Context

  • The sale was executed under a pre-established 10b5-1 plan (routine trading arrangement), which often indicates the sale was pre-planned rather than a spontaneous vote of confidence or concern.
  • RSU and option grants are awards that typically vest over service/vesting dates; they do not necessarily indicate immediate buying or selling of shares.
  • No indication in this filing that options were exercised for immediate sale (i.e., not a cashless exercise reported here).

If you want, I can check prior Form 4s for Persky to show how these grants fit into her historical compensation or ownership.

Insider Transaction Report

Form 4
Period: 2026-06-03
Xeris Biopharma Holdings, Inc.XERS
PERSKY MARLA
Director
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-06-03$5.90/sh−15,500$91,433→ 126,500 total
  • Award

    Common Stock

    [F3]
    2026-06-04+24,193→ 150,693 total
  • Award

    Stock Option (Right to Buy)

    [F5]
    2026-06-04$6.15/sh+32,996$202,925→ 32,996 total
    Exercise: $6.15Exp: 2036-06-04→ Common Stock (32,996 underlying)
Holdings

  • Common Stock

    [F4]
    (indirect: By Trust)
    6,370
Footnotes (5)
  • [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.810 to $5.960, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
  • [F4]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F5]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Signature
/s/ Beth Hecht, Attorney-in-Fact|2026-06-05

Documents

1 file
  • 4
    wk-form4_1780698568.xmlPrimary

    FORM 4